← ANALYST RATINGS · TIPRANKS
Medpace Holdings (MEDP): analyst forecast and price target
Analyst consensus
Hold2 Buy7 Hold0 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $623, the highest $700, the lowest $492. The average is +0.8% from the last price of $618.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Ann Hynes★★★★★★★★★★#1003 · hits 59% · avg +8.1% | Mizuho Securities | $665 → $700+5.3% | Buy | +13.2% | Reiterated | 07.10.26on TipRanks 07:26 | +0.5%next day +0.2% · 5 days +3.0% | ↗ |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $450 → $625+38.9% | Hold | +1.1% | Reiterated | 07.10.26on TipRanks 03:55 | +0.5%next day +0.2% · 5 days +3.0% | ↗ |
| Ryan Halsted★★★★★★★★★★#3317 · hits 60% · avg +9.0% | RBC Capital | $692 | Buy | +11.9% | Reiterated | 06.10.26on TipRanks 21:45 | +0.5%next day +0.2% · 5 days +3.0% | ↗ |
| Kevin Caliendo★★★★★★★★★★#2646 · hits 56% · avg +5.6% | UBS | $673 | Hold | +8.8% | Initiated | 30.09.26on TipRanks 05:40 | +0.5%next day −4.4% · 5 days −5.1% | ↗ |
| Jailendra Singh★★★★★★★★★★#12131 · hits 43% · avg −6.4% | Truist Financial | — | Hold | — | Reiterated | 17.09.26on TipRanks 08:09 | −1.3%next day −0.6% · 5 days 0.0% | ↗ |
| David Windley★★★★★★★★★★#769 · hits 59% · avg +9.3% | Jefferies | $515 → $560+8.7% | Hold | −9.5% | Reiterated | 14.09.26on TipRanks 11:25 | +1.8%next day +4.7% · 5 days +2.9% | ↗ |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $706 → $682−3.4% | Buy | +10.3% | Reiterated | 20.08.26on TipRanks 01:06 | — | |
| Ann Hynes★★★★★★★★★★#1003 · hits 59% · avg +8.1% | Mizuho Securities | $665 | Buy | +7.5% | Reiterated | 28.07.26on TipRanks Jul 29 08:20 | −3.4%next day +4.0% · 5 days −3.4% | ↗ |
| Sean Dodge★★★★★★★★★★#11980 · hits 43% · avg −4.3% | BMO Capital | $600 | Hold | −3.0% | Reiterated | 27.07.26on TipRanks Jul 28 08:45 | −2.0%next day −3.4% · 5 days −5.2% | ↗ |
| Eric Coldwell★★★★★★★★★★#1091 · hits 59% · avg +7.7% | Robert W. Baird | $547 → $624+14.1% | Hold | +0.9% | Reiterated | 24.07.26on TipRanks 07:21 | −0.8%next day −2.0% · 5 days −5.1% | ↗ |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $615 → $709+15.3% | Buy | +14.6% | Reiterated | 24.07.26on TipRanks 05:10 | — | |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $607 → $700+15.3% | Buy | +13.2% | Reiterated | 24.07.26on TipRanks 05:10 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $565 → $669+18.4% | Buy | +8.2% | Upgrade | 24.07.26on TipRanks 05:10 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $605 → $712+17.7% | Buy | +15.1% | Reiterated | 24.07.26on TipRanks 05:10 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $605 → $703+16.2% | Buy | +13.7% | Reiterated | 24.07.26on TipRanks 05:10 | — | |
| Ryan Halsted★★★★★★★★★★#3317 · hits 60% · avg +9.0% | RBC Capital | $484 → $692+43.0% | Buy | +11.9% | Reiterated | 23.07.26on TipRanks Jul 24 07:21 | +15.9%next day −0.8% · 5 days −5.0% | ↗ |
| Charles Rhyee★★★★★★★★★★#1937 · hits 54% · avg +5.6% | TD Cowen | $419 → $492+17.4% | Hold | −20.4% | Assigned | 23.07.26on TipRanks Jul 24 05:10 | +15.9%next day −0.8% · 5 days −5.0% | ↗ |
| Michael Cherny★★★★★★★★★★#2074 · hits 57% · avg +5.7% | Leerink Partners | $515 → $620+20.4% | Hold | +0.2% | Reiterated | 23.07.26on TipRanks Jul 24 05:10 | +15.9%next day −0.8% · 5 days −5.0% | ↗ |
| Justin Bowers★★★★★★★★★★#8679 · hits 47% · avg 0.0% | Deutsche Bank | $480 → $535+11.5% | Hold | −13.5% | Reiterated | 23.07.26on TipRanks Jul 24 05:10 | +15.9%next day −0.8% · 5 days −5.0% | ↗ |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $450 | Hold | −27.2% | Reiterated | 23.07.26on TipRanks Jul 24 05:10 | +15.9%next day −0.8% · 5 days −5.0% | ↗ |
| Jared Haase★★★★★★★★★★#1700 · hits 89% · avg +24.8% | William Blair | — | Hold | — | Reiterated | 23.07.26on TipRanks Jul 24 05:10 | +15.9%next day −0.8% · 5 days −5.0% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Medpace Holdings
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $591 at a price of $624 (−5.3%); now: $612 at $618 (−1.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 6 | 5 | 6 | 6 | 5 | 2 |
| Hold | 5 | 4 | 7 | 7 | 8 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 21.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $4.44 (from $4.31 to $4.64). Last quarter: $4.25.
Sales
Next quarter’s sales estimate — $714M (from $706M to $736M). Last quarter: $707M.
Best top-analyst consensus in the sector · Healthcare
About Medpace Holdings
- CEO: August James Troendle
- Employees: 6,500
- 5375 Medpace Way, Cincinnati, OH, 45227, US
- www.medpace.com
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Data from the stock’s TipRanks forecast page, read 34 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗